Journal of Internal Medicine Concepts & Practice ›› 2022, Vol. 17 ›› Issue (01): 29-37.doi: 10.16138/j.1673-6087.2022.01.006
• Expert forum • Previous Articles Next Articles
Received:2021-12-10
Online:2022-02-28
Published:2022-07-25
CLC Number:
| [1] |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases[J]. J Hepatol, 2009. 51(2): 237-267.
doi: 10.1016/j.jhep.2009.04.009 URL |
| [2] |
Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365.
doi: 10.1016/j.jhep.2019.04.001 URL |
| [3] |
Pedersen MR, Greenan G, Arora S, et al. Ursodeoxycholic acid decreases incidence of primary biliary cholangitis and biliary complications after liver transplantation[J]. Liver Transpl, 2021, 27(6):866-875.
doi: 10.1002/lt.25935 URL |
| [4] | Santiago P, Scheinberg AR, Levy C. Cholestatic liver diseases: new targets, new therapies[J]. Therap Adv Gastroenterol, 2018, 11: 1756284818787400. |
| [5] |
Kowdley KV, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67(5): 1890-1902.
doi: 10.1002/hep.29569 pmid: 29023915 |
| [6] | Guthrie G, Tackett B, Stoll B, et al. Long-term effect of obeticholic acid on transient elastography and ast to platelet ratio index in patients with PBC[J]. Gut, 2017, 66 Suppl 2: A98. |
| [7] |
Roberts SB, Ismail M, Kanagalingam G, et al. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis[J]. Hepatol Commun, 2020, 4(9): 1332-1345.
doi: 10.1002/hep4.1518 pmid: 32923836 |
| [8] |
Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643.
doi: 10.1056/NEJMoa1509840 URL |
| [9] |
Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67(9): 1568-1594.
doi: 10.1136/gutjnl-2017-315259 pmid: 29593060 |
| [10] | Schramm C, Hirschfield G, Wedemeyer H, et al. Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis[J]. J Hepatol, 2018, 68: S103. |
| [11] | Xie C, Takahashi S, Brocker CN, et al. Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(10): 1396-1411. |
| [12] | ANON. Bezafibrate add-on therapy improves liver transplantation-free survival in patients with primary biliary cholangitis[J]. Gastroenterol Hepatol (N Y), 2021, 17(2 Suppl 3): 10-11. |
| [13] |
Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181.
doi: 10.1056/NEJMoa1714519 URL |
| [14] |
de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies[J]. Gastroenterology, 2021, 160(3): 734-743.
doi: 10.1053/j.gastro.2020.10.001 URL |
| [15] |
Honda A, Tanaka A, Kaneko T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis[J]. Hepatology, 2019, 70(6): 2035-2046.
doi: 10.1002/hep.30552 URL |
| [16] | Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis[J]. Drug Des Devel Ther, 2015, 9: 5407-5419. |
| [17] | 郭元彪, 应海峰, 徐佳悦, 等. 熊去氧胆酸联合非诺贝特对原发性胆汁性胆管炎的临床疗效及安全性[J]. 现代生物医学进展, 2021, 21(14): 2670-2674. |
| [18] |
Ghonem NS, Auclair AM, Hemme CL, et al. Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol[J]. Clin Pharmacol Ther, 2020, 108(6): 1213-1223.
doi: 10.1002/cpt.1930 URL |
| [19] |
Reig A, álvarez-Navascués C, Vergara M, et al. Obeticholic acid and fibrates in primary biliary cholangitis: comparative effects in a multicentric observational study[J]. Am J Gastroenterol, 2021, 116(11): 2250-2257.
doi: 10.14309/ajg.0000000000001343 URL |
| [20] |
Soret PA, Lam L, Carrat F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2021, 53(10): 1138-1146.
doi: 10.1111/apt.16336 URL |
| [21] | Smets L, Liliane S, Korf H, et al. LBO-05-bezafibrate improves the effect of obeticholic acid on cholestasis in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 70(1): e130. |
| [22] |
Schattenberg JM, Pares A, Kowdley KV, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA[J]. J Hepatol, 2021, 74(6): 1344-1354.
doi: 10.1016/j.jhep.2021.01.013 pmid: 33484775 |
| [23] |
Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J]. Lancet Gastroenterol Hepatol, 2017, 2(10): 716-726.
doi: 10.1016/S2468-1253(17)30246-7 URL |
| [24] | Levy C, Bowlus C, Neff G, et al. Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study[J]. J Hepatol, 2020, 73: S464-S465. |
| [25] |
Xiao L, Pan G. An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: the apical sodium-dependent bile acid transporter (SLC10A2/ASBT)[J]. Clin Res Hepatol Gastroenterol, 2017, 41(5): 509-515.
doi: 10.1016/j.clinre.2017.02.001 URL |
| [26] |
Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis[J]. Hepatol Commun, 2019, 3(3): 365-381.
doi: 10.1002/hep4.1305 URL |
| [27] |
Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J]. Lancet, 2017, 389(10074): 1114-1123.
doi: S0140-6736(17)30319-7 pmid: 28187915 |
| [28] |
Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis[J]. Sci Rep, 2018, 8(1): 6658.
doi: 10.1038/s41598-018-25214-0 pmid: 29704003 |
| [29] |
Mayo MJ, Wigg AJ, Leggett BA, et al. NGM282 for treatment of patients with primary biliary cholangitis[J]. Hepatol Commun, 2018, 2(9): 1037-1050.
doi: 10.1002/hep4.1209 URL |
| [30] |
Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis[J]. Expert Opin Pharmacother, 2014, 15(3): 365-372.
doi: 10.1517/14656566.2014.873404 pmid: 24382005 |
| [31] |
Floreani A, Franceschet I, Perini L, et al. New therapies for primary biliary cirrhosis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 263-272.
doi: 10.1007/s12016-014-8456-5 URL |
| [32] |
Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomee[J]. Aliment Pharmacol Ther, 2016, 43(2): 283-293.
doi: 10.1111/apt.13465 URL |
| [33] |
Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA[J]. J Hepatol, 2021, 74(2): 321-329.
doi: 10.1016/j.jhep.2020.09.011 pmid: 32950590 |
| [34] | Arsenijevic A, Harrell CR, Fellabaum C, et al. Mesenchymal stem cells as new therapeutic agents for the treatment of primary biliary cholangitis[J]. Anal Cell Pathol (Amst), 2017, 2017: 7492836. |
| [35] |
Alfaifi M, Eom YW, Newsome PN, et al. Mesenchymal stromal cell therapy for liver diseases[J]. J Hepatol, 2018, 68(6): 1272-1285.
doi: 10.1016/j.jhep.2018.01.030 URL |
| [36] | Wang L, Li J, Liu H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28 Suppl 1: 85-92. |
| [37] |
Wang L, Han Q, Chen H, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J]. Stem Cells Dev, 2014, 23(20): 2482-2489.
doi: 10.1089/scd.2013.0500 pmid: 24835895 |
| [38] |
Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J]. Am J Gastroenterol, 2013, 108(6): 933-941.
doi: 10.1038/ajg.2013.51 URL |
| [39] |
Khanna A, Jopson L, Howel D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis[J]. Hepatology, 2019, 70(5): 1646-1657.
doi: 10.1002/hep.30099 URL |
| [40] |
Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J]. N Engl J Med, 2009, 360(24): 2544-2555.
doi: 10.1056/NEJMoa0810440 URL |
| [41] | Hirschfield GM, Gershwin ME, Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid[J]. Hepatology, 2016, 4(1): 189-199. |
| [42] |
Aoyama T, Paik YH, Watanabe S, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent[J]. Hepatology, 2012, 56(6): 2316-2327.
doi: 10.1002/hep.25938 URL |
| [43] |
Bettaieb A, Jiang JX, Sasaki Y, et al. Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice[J]. Gastroenterology, 2015, 149(2): 468-480.
doi: 10.1053/j.gastro.2015.04.009 pmid: 25888330 |
| [44] | Dalekos G, Invernizzi P, Nevens F, et al. GS-02-efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial[J]. J Hepatol, 2019, 70(1): e1-e2. |
| [45] |
Chapman MH, Thorburn D, Hirschfield GM, et al. British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis[J]. Gut, 2019, 68(8): 1356-1378.
doi: 10.1136/gutjnl-2018-317993 URL |
| [46] |
Fickert P, Hirschfield GM, Denk G, et al. NorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis[J]. J Hepatol, 2017, 67(3): 549-558.
doi: S0168-8278(17)32045-7 pmid: 28529147 |
| [47] |
Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase Ⅱ study of obeticholic acid for primary sclerosing cholangitis[J]. J Hepatol, 2020, 73(1): 94-101.
doi: S0168-8278(20)30160-4 pmid: 32165251 |
| [48] |
Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis[J]. Hepatology, 2019, 70(3): 788-801.
doi: 10.1002/hep.30509 URL |
| [49] |
Gerussi A, Invernizzi P. Better end points needed in primary sclerosing cholangitis trials[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 143-144.
doi: 10.1038/s41575-019-0110-5 URL |
| [50] |
Tabibian JH, Lindor KD. NGM282, an FGF19 analogue, in primary sclerosing cholangitis[J]. J Hepatol, 2019, 70(3): 348-350.
doi: S0168-8278(18)32623-0 pmid: 30626486 |
| [51] |
Lemoinne S, Pares A, Reig A, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience[J]. Clin Res Hepatol Gastroenterol, 2018, 42(6): 521-528.
doi: 10.1016/j.clinre.2018.06.009 URL |
| [52] | 沈波, 陆伦根. 肠道微生态在原发性硬化性胆管炎进展中的作用及治疗策略[J]. 肝脏, 2020, 25(12): 1256-1257. |
| [53] |
Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis[J]. Lancet, 2018, 391(10139): 2547-2559.
doi: 10.1016/S0140-6736(18)30300-3 URL |
| [54] |
Ali AH, Damman J, Shah SB, et al. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis[J]. Scand J Gastroenterol, 2020, 55(8): 941-950.
doi: 10.1080/00365521.2020.1787501 URL |
| [55] |
Deneau MR, Mack C, Mogul D, et al. Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis[J]. Hepatology, 2021, 73(3):1061-1073.
doi: 10.1002/hep.31560 URL |
| [56] |
Eksteen B, Bowlus CL, Montano-Loza AJ, et al. Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis[J]. Hepatol Commun, 2021, 5(3): 478-490.
doi: 10.1002/hep4.1619 pmid: 33681680 |
| [57] |
Hedin CRH, Sado G, Ndegwa N, et al. Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2020, 18(10): 2295-2304.
doi: 10.1016/j.cgh.2020.02.014 URL |
| [58] |
European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline[J]. J Hepatol, 2017, 66(6): 1265-1281.
doi: 10.1016/j.jhep.2017.02.013 URL |
| [59] |
Kaffes A, Griffin S, Vaughan R, et al. A randomized trial of a fully covered self-expandable metallic stent versus plastic stents in anastomotic biliary strictures after liver transplantation[J]. Therap Adv Gastroenterol, 2014, 7(2): 64-71.
doi: 10.1177/1756283X13503614 URL |
| [60] |
Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach[J]. Hepatol Int, 2021, 15(1): 6-20.
doi: 10.1007/s12072-020-10118-x pmid: 33377990 |
| [1] | XU Doudou, CHEN Ying, LÜ Ankang, WU Beiwen. A retrospective cohort study on the correlation between triglyceride-glucose index and new-onset fatty liver disease [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 301-306. |
| [2] | NING Ling, LIU Zhenjun, LI Wei, LIU Wen, LI Wei, ZHANG Zhenhua, FANG Weidong, GAO Youfang, ZHENG Xiaowei, LI Lei. Pathological and etiological analysis of cholestatic liver disease in Anhui [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 53-57. |
| [3] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 84-87. |
| [4] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 1-3. |
| [5] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 11-14. |
| [6] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 15-23. |
| [7] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 24-28. |
| [8] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 38-42. |
| [9] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 4-10. |
| [10] | . [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 43-47. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
